Cellectis S.A. (CLLS) Stock Forecast
CLLS analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 3.60 / 5 from 5 analysts
- Price target
- $4.83 average of analyst targets
- Upside to target
- +363.9% from the latest close
- Next earnings
- November 6, 2026
- 52-week range
- $1.04 – $5.35
CLLS analyst ratings
5 analystsNumber of analysts at each rating.
CLLS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CLLS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.23 | −$0.07 | $0.01 | −1,898.0% | 5 |
| Current fiscal year (2026) | −$0.78 | −$1.16 | −$0.50 | −$0.67 | −15.8% | 5 |
| Next fiscal year (2027) | −$0.71 | −$1.25 | −$0.41 | −$0.78 | +8.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CLLS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $13.5M | $8.7M | $17.0M | −57.9% | 4 |
| Current fiscal year (2026) | $49.7M | $29.9M | $66.3M | −28.1% | 4 |
| Next fiscal year (2027) | $45.2M | $21.6M | $64.5M | −8.9% | 4 |
CLLS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CLLS revenue: reported and forecast
CLLS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.22 | −$0.22 | −$0.20 | −$0.19 | −$0.18 | −20.0% | 5 up · 0 down |
| Current fiscal year (2026) | −$0.89 | −$0.89 | −$0.82 | −$0.79 | −$0.78 | −13.3% | 3 up · 2 down |
| Next fiscal year (2027) | −$0.89 | −$0.89 | −$0.82 | −$0.84 | −$0.71 | −19.4% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CLLS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CLLS beat in 7 of 12.
What analysts expect from CLLS
5 analysts cover Cellectis; their consensus rating is buy (3.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.83, 363.9% above the latest close of $1.04. Analysts expect earnings of −$0.78 per share for 2026, −15.8% from a year earlier. For 2027 the average estimate is −$0.71 per share on revenue of $45.2 million. Cellectis beat the EPS estimate in 7 of the last 12 quarters.
Related: CLLS income statement, CLLS key metrics, CLLS chart. See the CLLS stock overview for the latest quote and news.
CLLS forecast FAQ
What is Cellectis's price target?
The average analyst price target for Cellectis is $4.83, 363.9% above the latest close of $1.04.
Is Cellectis a buy, hold or sell?
Of 5 analysts covering Cellectis, 2 rate it a strong buy, 0 a buy, 2 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cellectis's EPS forecast?
Analysts forecast −$0.78 per share for 2026 (range −$1.16 to −$0.50); for 2027 the estimate is −$0.71.
What is Cellectis's revenue forecast?
The average revenue estimate for 2026 is $49.7 million, growth of −28.1%; for 2027 it is $45.2 million.
When does Cellectis report earnings?
Cellectis is expected to report results for the quarter ending September 30, 2026 on November 6, 2026.
Does Cellectis usually beat earnings estimates?
Cellectis reported EPS at or above the analyst estimate in 7 of the last 12 quarters.